Osteocyte-Targeting Peptide for 3D Bone Shape Remodeling
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for osteoarthritis and other hard tissue disorders fail to effectively slow, arrest, or reverse pathological 3D bone shape change, which is a sensitive predictor of joint degeneration and progression, and lack targeted mechanisms to stimulate TGF-β signaling in osteocytes without adverse effects.
Innovation Solution
A peptide that selectively binds to integrin αvβ3 expressed by osteocytes, with high affinity, is administered to stimulate osteocyte-mediated bone remodeling and TGF-β signaling, thereby slowing or reversing 3D bone shape change.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments (NSAIDs, corticosteroids, hyaluronic acid) are used to treat osteoarthritis, then pain relief or temporary symptom management is achieved, but they fail to effectively slow or reverse three-dimensional bone shape change and may cause adverse effects
Solution Approach 1:
The patent extracts and targets the specific molecular mechanism (integrin αvβ3) that drives pathological bone shape change in osteoarthritis. By isolating this specific target and developing a peptide that selectively binds to it, the treatment addresses the root cause of bone deformation without the broad-spectrum adverse effects of conventional medications like NSAIDs and corticosteroids
Solution Approach 2:
The peptide acts as an intermediary molecule that mediates the interaction between the treatment and the pathological process. It specifically binds to integrin αvβ3 on osteocytes, translating the therapeutic intent into targeted biological action that slows bone shape change without affecting other cell types or organs
2Reliability
If a peptide with high binding affinity to integrin αvβ3 is administered, then three-dimensional bone shape change is slowed or arrested, but selective binding to avoid other integrins is required
Solution Approach 1:
The peptide is designed with specific local properties (amino acid sequence: DLQERGDNDISPFSGDGQPFKD) that confer high affinity and selectivity for integrin αvβ3. This localized molecular design ensures the peptide interacts specifically with the target integrin on osteocytes while avoiding binding to other integrin subtypes, achieving both efficacy and selectivity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The peptide effectively slows or reverses pathological 3D bone shape change, improving joint function and reducing bone sclerosis, while promoting chondrocyte differentiation and cartilage matrix production, with significant clinical benefits.
Implementation Method 1
a peptide which binds integrin αvβ3 expressed by osteocytes
Implementation Method 2
the peptide is agonistic on binding to integrin αvβ3 expressed by osteocytes
Data Source
AI summary
Compounds, pharmaceutical compositions, and a method of treating hard tissue diseases and disorders are disclosed. The compounds may be a peptide and is structured to bind integrin αvβ3 expressed by osteocytes and by selective binding to the cell surface integrin on hard tissue forming cells regulate three-dimensional bone shape, cartilage formation and repair.